<PAGE> 1
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 13D
(Amendment No. 2)
Under the Securities Exchange Act of 1934
Ostex International, Inc.
- --------------------------------------------------------------------------------
(Name of Issuer)
Common Stock, $.01 par value
- --------------------------------------------------------------------------------
(Title of Class of Securities)
68859Q101
---------------------
(CUSIP Number)
Mary M. McDonald Merck & Co., Inc.
Senior Vice President One Merck Drive, Whitehouse Station,
and General Counsel NJ 08889-0100
- --------------------------------------------------------------------------------
(Name, Address, and Telephone Number of Person Authorized
to Receive Notices and Communications)
June 6, 1996
-------------------------------------------------------
(Date of Event which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to report
the acquisition which is the subject of this Schedule 13D, and is filing this
schedule because of Rule 13d-1(b)(3) or (4), check the following box [ ].
Check the following box if a fee is being paid with the statement [ ]. (A fee is
not required only if the reporting person: (1) has a previous statement of file
reporting beneficial ownership of more than five percent of the class of
securities described in Item 1; and (2) has filed no amendment subsequent
thereto reporting beneficial ownership of five percent or less of such class.)
(See Rule 13d-7).
Note: Six copies of this statement, including all exhibits, should be filed with
the Commission. See Rule 13d-1(a) for other parties to whom copies are to be
sent.
The information required on the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).
<PAGE> 2
Item 4. Purpose of the Transaction.
Item 4 is hereby amended to add the following information:
Merck acquired its investment in Ostex Common Stock as part of a
strategy to assist Ostex in its efforts to develop and commercialize its
product. Merck believes that these goals have been accomplished. Consequently,
Merck has determined to review its investment in Ostex Common Stock and may at
any time determine to sell some or all of its shares of Ostex Common Stock,
depending upon various factors including, but not limited to, the price of Ostex
Common Stock, subsequent developments affecting Ostex's business and prospects,
other opportunities available to Merck, general stock market and economic
conditions, and other factors Merck deems relevant.
Merck has no current plans or proposals which relate to, or would
result in, any changes specified in clauses (a) through (j) of Item 4 of
Schedule 13D.
<PAGE> 3
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.
Date: June 6, 1996
MERCK & CO., INC.
By: /s/ Celia A. Colbert
--------------------------------
Name: Celia A. Colbert
Title: Secretary
